The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia
MetadataShow full item record
Aim: The use of complementary and alternative medicine (CAM) by cancer patients is growing. However, few studies have examined the perceived benefits and adverse effects resulting from the use of CAM by cancer patients. The aim of this study was to evaluate CAM use by cancer patients and to explore their perceptions of the benefit, safety and efficacy of CAM in general. Methods: Oncologists from three university teaching hospitals screened patients for eligibility. Eligible patients (N = 1323) were mailed a letter of invitation with a questionnaire between January and May 2008. Results: Overall 381 questionnaires were returned, showing that 65% of cancer patients used at least one form of CAM. Patients considered taking biological CAM before, during and after chemotherapy. Up to 90% of CAM users believed that CAM provided potential health benefits and less than 3% reported adverse effects experienced from the use of CAM. Most respondents (80%) believed CAM can provide health benefits even when efficacy has not been proven. Most patients (90%) believed that doctors should consider learning about CAM to provide appropriate advice to their cancer patients, and most (83%) indicated they would be happier to accept CAM if it was offered by the hospital. Conclusion: A substantial portion of Australian cancer patients use CAM. Given the limited data on efficacy and safety for most CAM, it may be reasonable to offer CAM within the hospital environment so its use can be monitored and patients can receive more evidence-based care.
Showing items related by title, author, creator and subject.
Su, Q.; Sun, F.; Li, J.; Zhang, H.; Wang, M.; Zhou, Huaqiong; Qiao, L. (2015)© 2015 Indian Journal of Cancer | Pulished by Wolters Kluwer - Medknow.OBJECTIVE: To explore the relationship between Type 2 diabetes and primary liver cancer. MATERIALS AND METHODS: In the period from December 2008 to ...
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialCameron, David; Brown, Julia; Dent, Rebecca; Jackisch, Christian; Mackey, John; Pivot, Xavier; Steger, Guenther; Suter, Thomas; Toi, Masakazu; Parmar, Mahesh; Laeufle, Rita; Im, Young-Hyuck; Romieu, Gilles; Harvey, Vernon; Lipatov, Oleg; Pienkowski, Tadeusz; Cottu, Paul; Chan, Arlene; Im, Seock-Ah; Hall, Peter; Bubuteishvili-Pacaud, Lida; Henschel, Volkmar; Deurlog, Regula; Pallaud, Celine; Bell, Richard (2013)Background: The addition of bevacizumab to chemotherapy improves progression-free survival in metastatic breast cancer and pathological complete response rates in the neoadjuvant setting. Micrometastases are dependent on ...
Variation in adenoma detection rate and the lifetime benefits and cost of colorectal cancer screening: A microsimulation modelMeester, R.; Doubeni, C.; Lansdorp_Vogelaar, Iris; Jensen, C.; Van Der Meulen, M.; Levin, T.; Quinn, V.; Schottinger, J.; Zauber, A.; Corley, D.; Van Ballegooijen, M. (2015)Importance: Colonoscopy is the most commonly used colorectal cancer screening test in the United States. Its quality, as measured by adenoma detection rates (ADRs), varies widely among physicians, with unknown consequences ...